Medical Advocates for Social Justice

   Medical Advocates for Social Justice

  Conference Highlights:
Select Conference Abstracts and Posters
from the

   

 


 

 		4th International Workshop on the Clinical
Pharmacology of HIV Therapy
Cannes, France



 March 27-29, 2003		  
 
Main New/Newsworthy  Conference Updates : Main Page Home
Last Update:  February 21, 2007
Documents identified with this icon  are in Portable Document Format (PDF) and require the Adobe Acrobat Reader 5 and may take a few minutes to download.
Recent Additions
Date   Format   Document
         
July 07   Abstract   Sex differences in zidovudine (ZDV) and lamivudine (3TC) triphosphate (TP)
concentrations in HIV-infected patients
         
July 07   Poster   Incidence of nephrolithiasis induced with indinavir plus ritonavir (boosting dose) in
HIV infected patients
Drug Data
Protease Inhibitors: General Data
 
 

PDF CONFERENCE POSTER
Inhibitory Quotient (IQ) of Protease Inhibitors (PIs) Using a Standardized Determination of IC50

Stevens RC,  Kakuda TN,  Bertz R, et al
Poster

 
PDF CONFERENCE POSTER
The effect of antiretroviral protease inhibitors on P-gp expression in CD4 and CD8 subpopulations of lymphocytes.
Ford J, Chandler B, Khoo SH, Back DJ , et al.
 Poster
 
Detection of protease inhibitors in plasma and saliva of patients receiving different HAART regimens
C Atzori, P Villani, M Ragazzi, et al.
Abstract


NNRTIs: General
 
  Efavirenz and Nevirapine concentration-effect relationships in HIV infected patients
pharmacologically followed by routine therapeutic drug monitoring (TDM)
Garraffo R, Lavrut T, Pierre B, et al.
Abstract

Drug-Specific Data

Amprenavir

  Rifabutin Given Twice Weekly With Ritonavir-Boosted Amprenavir in a Once-Daily HAART Regimen May Result in Sub-Therapeutic Levels of Rifabutin Despite Directly Observed Treatment.
C Boulanger , B Ha, M Desrosiers, et al.
 Abstract

Capravirine

  CONFERENCE PDF POSTER
Integrated Adherence, Pharmacokinetic, and Pharmacodynamic Modeling to Design a Dose-Ranging Study of Capravirine with Kaletra in Treatment-Experienced Patients.
P Hawley, M Amantea, B. Poland. et al
 Poster
 
CONFERENCE PDF POSTER
Pharmacokinetic Model of Capravirine (CPV), a Novel Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), Co-Administered with Kaletra (KLT) in Healthy and HIV-Infected Subjects.
M Amantea, S. Raber, R. Pesano, et al.
 Poster

Didanosine

  CONFERENCE PDF POSTER
Pharmacokinetic Evaluation of Reduced Doses of Didanosine Enteric Coated Capsules (ddI EC) in Combination with Tenofovir Disoproxil Fumarate  (TDF) and Food for a Once-Daily Antiretroviral Regimen.
S Kaul , B Damle , K Bassi,  et al
Poster

Efavirenz
 
 
CONFERENCE PDF POSTER
 Therapeutic Drug Monitoring of Efavirenz in HIV-infected patients treated by Sustiva associated or not with ritonavir.
S Faroux,  M Berhoune ,  H Sauvageon-Martre, et al
 Poster
 

CONFERENCE PDF POSTER
Efavirenz plasma concentrations in Portuguese  HIV infected subjects 
S A Pereira, RM Côrte-Real, T. Branco, et al
 Poster

Efavirenz and Nevirapine concentration-effect relationships in HIV infected patients pharmacologically followed by routine therapeutic drug monitoring (TDM)
Garraffo R, Lavrut T, Pierre B, et al.
Abstract


Indinavir
 
 

CONFERENCE PDF POSTER
Steady-State Pharmacokinetics and Tolerability of Indinavir When Co-Administered With Lopinavir/r in Antiretroviral-Experienced Subjects.
A Tseng, E Phillips, T Antoniou, et al
 Poster
 
CONFERENCE PDF POSTER
 MDR1 genotypes associated with antiviral dynamics and indinavir (IDV) disposition in HIV-infected patients
PL Anderson, J Lamba, E Schuetz, CV Fletcher.
 Poster   Abstract
 
CONFERENCE PDF POSTER
Incidence of nephrolithiasis induced with indinavir plus ritonavir (boosting dose) in HIV infected patients
G Dragovic, DJ Jevtovic  
 Poster        Abstract

Lamivudine
 
  Sex differences in zidovudine (ZDV) and lamivudine (3TC) triphosphate (TP) concentrations in HIV-infected patients
PL Anderson TN Kakuda, SP Kawle, et al
Abstract

Lopinavir
 
 
CONFERENCE POWER-POINT POSTER
 Lopinavir plasma concentrations and lipid elevation patterns in patients on lopinavir/ritonavir-containing regimens.
M Boffito, S Bonora, A Sinicco, et al.
Poster     Abstract
 

CONFERENCE PDF POSTER
 Effect of LPV trough level on the biological markers of cardiovascular risk in LPV/r treated HIV infected patients
 Valerio L., Fontas E., Garraffo R., et al
 Abstract    Poster
 

CONFERENCE PDF POSTER
 Simplifying Therapeutic Drug Monitoring for Twice Daily Regimens of Kaletra
C Alexander J. Montaner,  J. Asselin et al
 Poster
 
Lack of drug-drug interaction between lopinavir and  saquinavir based on their trough plasma concentrations  in highly HIV-experienced
patients treated with Kaletra and Invirase.  
JM Poirier , O Zouai , JL Meynard , et al
 Abstract
 

Nelfinavir
 
  CONFERENCE PDF POSTER
Improved Gastrointestinal (GI) Tolerability of Roche Nelfinavir 625 mg Film-Coated Tablets in Comparison with Nelfinavir 250 mg Film-Coated Tablets (Viracept)
B Kaeser, D-J Akintola, A Saifulanwar,et al
 Poster
 
CONFERENCE PDF POSTER
Variability in Alpha-1 Acid Glycoprotein and its Impact on Nelfinavir Free Fraction in HIV-Infected Subjects
S Au, A Gates, T Blaschke, et al.
Poster
 
Efavirenz and Nevirapine concentration-effect relationships in HIV infected patients pharmacologically followed by routine therapeutic drug monitoring (TDM)
Garraffo R, Lavrut T, Pierre B, et al.
Abstract
 

Clinical pharmacokinetics of nelfinavir and its metabolite M8 in HIV/HCV co-infected patients with and without cirrhosis.
MB Regazzi, P.Villani, P. Zucchi,  et al 
 Abstract

Nevirapine
 
  CONFERENCE PDF POSTER
 Quality-Control Analysis of Generic Nevirapine Formulations in the Developing World: An Initial Report (Note These results were alsopublished as a research letter in the May 28 issue of JAMA)
Penzak SR, Acosta EP, J Tavel JA, et al
 Poster

CONFERENCE PDF POSTER
Relationship between nevirapine plasma concentration and abnormal liver functiontests in a cohort of heterogeneous HIV+ patients
Almond L, Boffito M, Hoggard P
 Poster

Ritonavir
 
  CONFERENCE PDF POSTER
 Evaluation of Single and Multiple Dose Pharmacokinetics of Ritonavir in Subjects with Mild
or Moderate Hepatic Insufficiency
J. Peng, R. Bertz, A. Hsu, et al.
Poster

Saquinavir
 
  CONFERENCE PDF POSTER
Pharmacokinetics of Saquinavir hard gel (Invirase) when combined with Atazanavir
D Prelutsky, P Salvato, R Falcon. et al
 Poster
 

Zidovudine
 
  Sex differences in zidovudine (ZDV) and lamivudine (3TC) triphosphate (TP)
concentrations in HIV-infected patients
PL Anderson TN Kakuda, SP Kawle, et al
Abstract
Therapeutic Drug Monitoring
  CONFERENCE PDF POSTER
HIV Drug Interaction and Antiretroviral (ARV) Therapeutic Drug Monitoring (TDM) Registry:
Attaining Compliance With Clinical Laboratory Improvement Act (CLIA) and the Health
Insurance Portability and Accountability Act (HIPPA)
J Slish, LCatanzaro, L Esch, et al.
Poster
 
CONFERENCE PDF POSTER
Therapeutic Drug Monitoring of Efavirenz in HIV-infected patients treated by Sustiva associated
or not with ritonavir.
S Faroux,  M Berhoune ,  H Sauvageon-Martre, et al
 Poster
 
CONFERENCE PDF POSTER
 Simplifying Therapeutic Drug Monitoring for Twice Daily Regimens of Kaletra
C Alexander J. Montaner,  J. Asselin et al
Poster

Efavirenz and Nevirapine concentration-effect relationships in HIV infected patients
pharmacologically followed by routine therapeutic drug monitoring (TDM)
Garraffo R, Lavrut T, Pierre B, et al.
Abstract
Infrastructure
 

Transitioning an Established Antiretroviral Adherence-
Pharmacology Unit to Developing Countries.
C Maponga, M Simoyi, L Esch, et al
 Abstract
Mother-to-Child Transmission
  Overexpression of mdr1 in placentas from HIV-infected women.
 Camus M, Deloménie C, Faye A, et al.
 Abstract
Main New/Newsworthy  Conference Updates : Main Page Home

4th International Workshop on the Clinical Pharmacology of HIV Therapy
Select Posters and Abstracts
A Medical Advocates for Social Justice Update